Lead Product(s): CSF-1
Therapeutic Area: Ophthalmology Product Name: PresbiDrops
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Bluestem Capital
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing September 10, 2020
Proceeds from the financing will be used to advance Orasis’ lead eye drop candidate for the treatment of presbyopia symptoms through completion of its Phase 3 clinical trials.